about
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of harmful effects in non-randomised studiesMethylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescentsAntibiotics for secondary prevention of coronary heart diseaseSocial skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 yearsLevamisole for chronic hepatitis BSocial skills training for children with attention deficit hyperactivity disorder (ADHD)Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trialsQuetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial
P50
Q22061981-12048F16-D939-4615-9599-36BC0298B7FCQ24186221-3876D734-B23D-4C49-8800-858BC7D7051FQ24198192-DA233D67-8A08-4121-9570-56BB60B05D15Q24201388-0938585E-29B1-4B18-8353-079394CEB465Q24234231-FD1B5F03-3B49-4567-802C-282AE978799CQ24236771-01E9C133-F49E-4EE2-9FA3-C0AEC5FB5758Q24239933-2AD14AC0-B0F4-4B89-9467-B72D5DAA1C2BQ27007856-A4258629-0A69-4AA3-8F67-7182A65EE66BQ34486230-95B62BFF-FCD5-440B-8B1B-163BC9D5DBFE
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria Skoog
@ast
Maria Skoog
@en
Maria Skoog
@es
Maria Skoog
@nl
Maria Skoog
@sl
type
label
Maria Skoog
@ast
Maria Skoog
@en
Maria Skoog
@es
Maria Skoog
@nl
Maria Skoog
@sl
prefLabel
Maria Skoog
@ast
Maria Skoog
@en
Maria Skoog
@es
Maria Skoog
@nl
Maria Skoog
@sl